Table 2 Patient Demographics
From: Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer’s disease spectrum
ID | AAD | Sex | Path Diagnosis | APOE | Braak stage | Thal stage | CERAD | ABC | Mutation |
|---|---|---|---|---|---|---|---|---|---|
sAD1 | 56-60 | F | AD | 33 | VI | 5 | 2 | A3B3C2 | NA |
sAD2 | 63-67 | M | AD | 44 | VI | 5 | 3 | A3B3C3 | NA |
sAD3 | 67-69 | M | AD | 34 | VI | 5 | 3 | A3B3C3 | NA |
sAD4 | 64-68 | F | AD | 33 | VI | 5 | 3 | A3B3C3 | NA |
sAD5 | 77-80 | M | AD | 33 | VI | 5 | 3 | A3B3C3 | NA |
sAD6 | 68-70 | F | AD | 34 | VI | 5 | 2 | A3B3C2 | NA |
sAD7 | 62-64 | M | AD | 33 | VI | 5 | 3 | A3B3C3 | NA |
sAD8 | 63-65 | F | AD | 34 | VI | 5 | 3 | A3B3C3 | NA |
sAD9 | 65-67 | F | AD | 33 | VI | 5 | 3 | A3B3C3 | NA |
sAD10 | 68-70 | F | AD | 44 | VI | 5 | 2 | A3B3C2 | NA |
sAD11 | 73-75 | M | AD | 44 | VI | 5 | 3 | A3B3C3 | NA |
sAD12 | 85-88 | F | AD | 34 | VI | 5 | 3 | A3B3C3 | NA |
fAD1 | 45-48 | M | FAD | 33 | V | 5 | 3 | A3B3C3 | PSEN1 A434T & T291A |
fAD2 | 64-67 | F | FAD | 34 | VI | 5 | 3 | A3B3C3 | PSEN1 after 200 (R278I) |
fAD3 | 50-52 | F | FAD | 44 | VI | 5 | 3 | A3B3C3 | PSEN1 Intron 4 |
fAD4 | 36-39 | F | FAD | 33 | VI | 5 | 3 | A3B3C3 | PSEN1 E120K |
fAD5 | 57-60 | F | FAD | 34 | VI | 5 | 3 | A3B3C3 | PSEN1 E184D |
fAD6 | 49-52 | M | FAD | 33 | VI | 5 | 3 | A3B3C3 | PSEN1 mutation (Intron 4) |
CUAP1 | 90-92 | F | Pathological ageing | 33 | IV | 5 | 2 | A3B2C2 | NA |
CUAP2 | 85-88 | F | Pathological ageing | 34 | IV | 4 | 2 | A3B2C2 | NA |
CUAP3 | 85-87 | F | Pathological ageing | 34 | I | 4 | 1 | A3B1C1 | NA |
CUAP4 | 102-104 | F | Pathological ageing | 23 | IV | 5 | 1 | A3B2C1 | NA |
CUAP5 | 90-92 | F | Pathological ageing | 34 | IV | 5 | 2 | A3B2C2 | NA |
